Analyst firms · BofA Securities · PRCT

BofA Securities PRCT price target and rating history

PROCEPT BioRobotics Corporation (PRCT) · Health Care

BofA Securities rates PROCEPT BioRobotics Corporation (PRCT) Underperform with a $20 price target, as of its latest action on Feb 26, 2026. It has published 4 rating actions on PRCT since October 2021, including 0 upgrades and 2 downgrades. Across 8 firms with a PRCT price target in the last 12 months, the median target is $27. BofA Securities's $20 is 26% below that.

Current rating
Underperform
Price target
$20
Median target, all firms
$27
Actions on PRCT
4

BofA Securities price target on PRCT

$48$34$2020222023202420252026
BofA Securities price target on PRCT, each point a stated target, October 2021 to February 2026.

Every BofA Securities rating on PRCT

How other firms rate PRCT

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
BarclaysOverweight$30Oct 7, 2026
William BlairMkt PerformAug 5, 2026
Wells FargoEqual Weight$19Aug 5, 2026
UBSNeutral$20Jul 28, 2026
Truist SecuritiesHold$25Jul 6, 2026
Evercore ISIOutperform$30Jun 24, 2026
Leerink PartnersMarket Perform$29Jun 11, 2026
Robert W. BairdNeutral$30Mar 6, 2026
OppenheimerPerformFeb 26, 2026
BofA SecuritiesUnderperform$20Feb 26, 2026

Questions about BofA Securities and PRCT

What is BofA Securities's price target for PRCT?
BofA Securities's latest stated price target for PROCEPT BioRobotics Corporation (PRCT) is $20, from its action on Feb 26, 2026.
What is BofA Securities's rating on PRCT?
BofA Securities rates PRCT Underperform, a bearish rating, as of Feb 26, 2026.
When did BofA Securities last change its view on PRCT?
On Feb 26, 2026, BofA Securities downgrades to Underperform from Neutral, price target $20.
How does BofA Securities's PRCT target compare with other analysts?
Across 8 firms with a PRCT price target in the last 12 months, the median target is $27. BofA Securities's $20 is 26% below that.

More PRCT rating histories

All BofA Securities ratingsPRCT news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.